HFS
BIB icon

Hantz Financial Services’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Hantz Financial Services’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-178
Closed -$9K – 2187
2025
Q1 		$9K Hold
178
– – ﹤0.01% 983
2024
Q4 		$9K Hold
178
– – ﹤0.01% 822
2024
Q3 		$11K Hold
178
– – ﹤0.01% 782
2024
Q2 		$11K Hold
178
– – ﹤0.01% 788
2024
Q1 		$10K Hold
178
– – ﹤0.01% 824
2023
Q4 		$10K Hold
178
– – ﹤0.01% 801
2023
Q3 		$9K Hold
178
– – ﹤0.01% 809
2023
Q2 		$9K Hold
178
– – ﹤0.01% 789
2023
Q1 		$10K Hold
178
– – ﹤0.01% 774
2022
Q4 		$10K Hold
178
– – ﹤0.01% 749
2022
Q3 		$8K Hold
178
– – ﹤0.01% 769
2022
Q2 		$9K Hold
178
– – ﹤0.01% 754
2022
Q1 		$11K Buy
+178
New +$10.9K ﹤0.01% 773

Other funds holding BIB

CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
WWM
Westwood Wealth Management Los Angeles, California $255M AUM 54.97% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PSFG
Park Square Financial Group Roswell, Georgia $13.2M AUM 23.63% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
GC
Garde Capital Seattle, Washington $1.67B AUM 13.9% 1-Year Est. Return

Hantz Financial Services's BIB Position: Q2 2025 in Review

Hantz Financial Services sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2025, closing a stake of 178 shares — an estimated $9K sold.

Hantz Financial Services first reported a position in BIB in Q1 2022 and held it in 13 quarters. The position peaked at $11K in Q3 2024. 17 funds tracked by Wall St. Rank hold BIB as of Q2 2025.

  • Hantz Financial Services reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Hantz Financial Services sold 178 ProShares Ultra NASDAQ Biotechnology shares in Q2 2025, an estimated $9K.
  • Hantz Financial Services first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2022 and held it in 13 quarters.
  • Hantz Financial Services's ProShares Ultra NASDAQ Biotechnology position peaked at $11K in Q3 2024.
  • 17 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2025.

Based on Hantz Financial Services's 13F filing for Q2 2025, filed 4 Aug 2025.